HCA vs PGEN: fair value comparison
HCA Healthcare, Inc. and Precigen, Inc. · Updated 2026-10-19
PGEN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, HCA currently ranks higher by quality score.
| HCA | PGEN | |
|---|---|---|
| Verdict | Fairly valued | Awaiting full valuation |
| Last price | $451.09 | $6.38 |
| 12-month range | $361.32–$545.13 | $3.10–$8.56 |
| Rank by discount to fair value | #56 of 108 Healthcare | — |
| Rank by quality score | #157 of 301 Healthcare | #159 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | High |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: HCA fair value analysis · PGEN fair value analysis